Stock Research for ATAI

ATAI

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ATAI Stock Chart & Research Data

The ATAI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ATAI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ATAI Due diligence Resources & Stock Charts

The ATAI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ATAI Detailed Price Forecast - CNN Money CNN View ATAI Detailed Summary - Google Finance
Yahoo View ATAI Detailed Summary - Yahoo! Finance Zacks View ATAI Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ATAI Trends & Analysis - Trade-Ideas Barrons View ATAI Major Holders - Barrons
NASDAQ View ATAI Call Transcripts - NASDAQ Seeking View ATAI Breaking News & Analysis - Seeking Alpha
Spotlight View ATAI Annual Report - CompanySpotlight.com OTC Report View ATAI OTC Short Report - OTCShortReport.com
TradeKing View ATAI Fundamentals - TradeKing Charts View ATAI SEC Filings - Bar Chart
WSJ View Historical Prices for ATAI - The WSJ Morningstar View Performance/Total Return for ATAI - Morningstar
MarketWatch View the Analyst Estimates for ATAI - MarketWatch CNBC View the Earnings History for ATAI - CNBC
StockMarketWatch View the ATAI Earnings - StockMarketWatch MacroAxis View ATAI Buy or Sell Recommendations - MacroAxis
Bullish View the ATAI Bullish Patterns - American Bulls Short Pains View ATAI Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ATAI Stock Mentions - StockTwits PennyStocks View ATAI Stock Mentions - PennyStockTweets
Twitter View ATAI Stock Mentions - Twitter Invest Hub View ATAI Investment Forum News - Investor Hub
Yahoo View ATAI Stock Mentions - Yahoo! Message Board Seeking Alpha View ATAI Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ATAI - SECform4.com Insider Cow View Insider Transactions for ATAI - Insider Cow
CNBC View ATAI Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ATAI - OTC Markets
Yahoo View Insider Transactions for ATAI - Yahoo! Finance NASDAQ View Institutional Holdings for ATAI - NASDAQ


Stock Charts

FinViz View ATAI Stock Insight & Charts - FinViz.com StockCharts View ATAI Investment Charts - StockCharts.com
BarChart View ATAI Stock Overview & Charts - BarChart Trading View View ATAI User Generated Charts - Trading View




Latest Financial News for ATAI


atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
Posted on Wednesday April 24, 2024

The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression.Initial results from the recently completed monotherapy Part 1 of the study were shared in March 2024, and showed that a single dose of BPL-003 was safe and well-tolerated, with a rapid and durable antidepressant effect lasting up to 12-weeks post-dose. Part 2 of the study will investigate a single dose of BPL-003 in patients who are


atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
Posted on Wednesday April 17, 2024

BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally.BPL-003 was shown to be safe and well-tolerated with a predictable pharmacokinetic profile and a reliable induction of subjective psychedelic effects with single doses of up to 12 mg in healthy participants.Subjective psychedelic effects correlated with 5-MeO-DMT exposure and had a rapid onset and short duration, with acute effects resolving in less than two hours. NEW YOR


Atai Life Sciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Posted on Monday April 01, 2024

Atai Life Sciences ( NASDAQ:ATAI ) Full Year 2023 Results Key Financial Results Net loss: US$40.2m (loss narrowed by...


atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
Posted on Thursday March 28, 2024

Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato®Initial BPL-003 (intranasal 5-MeO-DMT) Phase 2a open-label results demonstrated a rapid and durable antidepressant effect through three months in TRD patients; top-line results from a controlled Phase 2b TRD study anticipated in 2H 2024Dosing commenced in VLS-01 (oral transmucosal DMT) Phase 1b study, with optimized


Stock Market & Investing Books

Enter a stock symbol to view the stock details.